Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c

Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.17 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $34.36 million versus the consensus estimate of $8.01 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Activist investors push Seer, Inc. to disclose go-private timeline
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)